30 Nov 2022 by admin in UncategorizedComments Kira Pharmaceuticals Announces First Cohort of Patients Dosed
30 Nov 2022 by admin in UncategorizedComments Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
17 Nov 2022 by admin in UncategorizedComments Laronde Appoints Pablo J. Cagnoni as Chief Executive Officer
15 Nov 2022 by admin in UncategorizedComments NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
14 Nov 2022 by admin in UncategorizedComments Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
14 Nov 2022 by admin in UncategorizedComments Arcellx Reports Third Quarter 2022 Financial Results And Business Progress
08 Nov 2022 by admin in UncategorizedComments Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
08 Nov 2022 by admin in UncategorizedComments Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
07 Nov 2022 by admin in UncategorizedComments Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
03 Nov 2022 by admin in UncategorizedComments NextCure Provides Update and Reports Third Quarter 2022 Financial Results
03 Nov 2022 by admin in UncategorizedComments Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
03 Nov 2022 by admin in UncategorizedComments Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
27 Oct 2022 by admin in UncategorizedComments NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
17 Oct 2022 by admin in UncategorizedComments Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
03 Oct 2022 by admin in UncategorizedComments Kira Pharmaceuticals Receives FDA Clearance of IND Application for Phase 2 Evaluation of KP104 in Systemic Lupus Erythematosus Associated Thrombotic Microangiopathy (SLE-TMA)
21 Sep 2022 by admin in UncategorizedComments OriCell Therapeutics Receives Implied License from NMPA for Ori-C101 IND Application
16 Sep 2022 by admin in UncategorizedComments Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
15 Sep 2022 by admin in UncategorizedComments Syros and Tyme Technologies Announce Stockholder Approval of Merger
07 Sep 2022 by admin in UncategorizedComments Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer
31 Aug 2022 by admin in UncategorizedComments Innoforce, Mayo Clinic & Hibiscus BioVentures launch Mayflower BioVentures
15 Aug 2022 by admin in UncategorizedComments Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates August 10, 2022
08 Aug 2022 by admin in UncategorizedComments Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
04 Aug 2022 by admin in UncategorizedComments NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
04 Aug 2022 by admin in UncategorizedComments Laronde Appoints John Mendlein as Chief Executive Officer
03 Aug 2022 by admin in UncategorizedComments Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
01 Aug 2022 by admin in UncategorizedComments Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
01 Aug 2022 by admin in UncategorizedComments OriCell Therapeutics Raises Over $120 Million in Series B Financing
01 Aug 2022 by admin in UncategorizedComments KIRA PHARMACEUTICALS APPOINTS ANGELA YAN AS PRESIDENT OF CHINA AND ASIA DEVELOPMENT AND OPERATIONS
28 Jul 2022 by admin in UncategorizedComments KIRA PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR KP104, A BIFUNCTIONAL ANTIBODY FUSION PROTEIN, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
06 Jul 2022 by admin in UncategorizedComments Crescendo Biologics announces nomination of second proprietary clinical candidate from immuno-oncology Humabody VH development portfolio
06 Jul 2022 by admin in UncategorizedComments NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec- 15-positive Tumors as reported in Laboratory Investigation
05 Jul 2022 by admin in UncategorizedComments Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
22 Jun 2022 by admin in UncategorizedComments Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annua
21 Jun 2022 by admin in UncategorizedComments Therorna completes Series A financing to accelerate pipeline development and clinical transformation of circRNA-based platform
21 Jun 2022 by admin in UncategorizedComments Arcellx Announces Closing Of Upsized Public Offering Of Common Stock And Underwriters’ Full Exercise Of Option To Purchase Additional Shares
21 Jun 2022 by admin in UncategorizedComments Arcellx Announces Appointment Of Maryam Abdul-Kareem As General Counsel
